News

Most allergist-immunologists who treat people with hereditary angioedema (HAE) think genetic testing may be useful in diagnosing irregular cases, but many say they require more education to feel confident with the specifics of testing, a study reports. “The study found that [health care providers] consider genetic testing during a…

Andembry (garadacimab), a first-in-class treatment to prevent swelling attacks in people with hereditary angioedema (HAE), ages 12 and older, is now available in Japan. The treatment was approved by Japan’s Ministry of Health, Labour and Welfare in February, Andembry is the first prophylactic (preventive) therapy in Japan that…

A man in his 60s who developed severe angioedema after the use of an ACE, or angiotensin-converting enzyme, inhibitor to treat high blood pressure required several emergency interventions before making a full recovery, according to a case study from France. Swelling in the man’s throat obstructed his breathing, ultimately…

A simple diagnostic score may help distinguish between two types of angioedema — mast cell-mediated angioedema and drug-induced nonallergic angioedema — in people taking angiotensin-converting enzyme (ACE) inhibitors, researchers said. They described the scoring system in the study, “Angiotensin-converting enzyme inhibitor-induced angioedema: Proposal for a diagnostic…

People from underrepresented racial and ethnic groups who have hereditary angioedema (HAE) continue facing barriers to diagnosis and effective care, according to a recent study. These patients reported having trouble getting adequate care before their diagnosis, and though most were satisfied with the treatment they received afterward, many…

Kaken Pharmaceutical obtained the rights to commercialize sebetralstat, an on-demand treatment for hereditary angioedema (HAE), in Japan under a licensing agreement with the HAE treatment’s developer, Kalvista Pharmaceuticals. Under the terms of the agreement, Kalvista will be eligible to receive an upfront payment of $11 million,…

The prevalence of certain conditions — namely, allergies, autoimmune diseases, and asthma — is higher among people with hereditary angioedema (HAE) than in the general population, according to a new study from Canada. The data specifically showed that the proportion of HAE patients who reported having autoimmune conditions was…

Deucrictibant, an oral therapy being developed for bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema, has been granted orphan drug status in the European Union. This designation, granted by the European Commission, intends to back the development of therapies to diagnose, prevent, or treat rare…

Keeping symptoms of hereditary angioedema (HAE) under control is the most important factor contributing to a better quality of life, according to a study carried out by scientists reporting from India and noting severe limits on access to first-line medications there. “There is an urgent need for easy availability…

A Phase 3 clinical trial testing sebetralstat as an on-demand treatment for swelling attacks in children with hereditary angioedema (HAE) has completed enrollment a year ahead of schedule. The trial’s initial target enrollment was surpassed in less than seven months, according to KalVista Pharmaceuticals, which is developing…